Synlogic Inc
Change company Symbol lookup
Select an option...
SYBX Synlogic Inc
MASI Masimo Corp
FAZE FaZe Holdings Inc
SSP E W Scripps Co
NHWK NightHawk Biosciences Inc
ELIQ Electriq Power Holdings Inc
GREE Greenidge Generation Holdings Inc
OAKU Oak Woods Acquisition Corp
WM Waste Management Inc
WST West Pharmaceutical Services Inc

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. The Company uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunological diseases. The Company also has a research collaboration with Roche on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease (IBD). The Company has also developed two drug candidates through a research collaboration with Ginkgo Bioworks, Inc: SYNB1353, designed to consume methionine for the potential treatment of homocystinuria (HCU), and SYNB2081, designed to lower uric acid for the potential treatment of gout.

Day's Change
-0.08 (-2.85%)
B/A Size
Day's High
Day's Low

Today's volume of 21,234 shares is on pace to be much lighter than SYBX's 10-day average volume of 87,070 shares.


Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.